What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?
Condition(s) studied
Investigational drug(s) / intervention(s)
screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice: women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
Study summary
Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy.
Eligibility
Primary outcome measure(s)
- To compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals — 6 years
Cumulative breast cancer risk will computed as the ratio between the number of stage 2 or higher cancers and the total number of women in the arm. The comparison between arms will be performed using the two proportion Z-test. 95% confidence intervals will also be computed
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Irst Irccs | Meldola (FC) | FC | Recruiting |
| Istituto per lo studio, la prevenzione e la rete oncologica (ISPRO) | Florence | Italy | Not Yet Recruiting |
| AUSL Romagna | Forlì | Italy | Recruiting |
| AOU Città della Salute e della Scienza | Torino | Italy | Not Yet Recruiting |
More Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04590560 on ClinicalTrials.gov ↗ ← All trials in Italy